FINNENCE ▪ THE WIRE FILE
THE WIRE · № 78856
News▲ Bullish
Finance Watch: 2026 Biopharma IPO Total Doubles Last Year’s Number
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES3
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Doubling biopharma IPO count signals reopening risk appetite for early-stage biotech funding.
Biotech IPO window reopening versus last year
CATALYST TO WATCH
Next biopharma pricing and debut performance
MAIN RISK
IPO supply can pressure secondary valuations
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare, XBI
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)2026-10-14 02:17 UTC
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)2026-10-14 02:17 UTC
←CORRELATIONshares Healthcare
Johnson & Johnson CFO Joseph Wolk: 'You can't heap enough praise on the pharma unit'2026-10-13 16:30 UTC
Johnson & Johnson CFO Joseph Wolk: 'You can't heap enough praise on the pharma unit'2026-10-13 16:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.